Euroopa Liit - malta - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - papillomavirus uman tip 6 l1 proteina, tal-papillomavirus uman tip 11 l1 proteina, tal-papillomavirus uman tip 16 l1 proteina, tal-papillomavirus uman tip 18 l1 proteina - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vaċċini - gardasil huwa vaċċin għall-użu mill-età ta'9 snin għall-prevenzjoni ta': leżjonijiet ġenitali premalinni (ċervikali, tal-vulva u vaġinali), premalignant leżjonijiet anali, 'kanċers ċervikali u kanċer anali każwalment relatat ċerti onkoġeniċi-papillomavirus uman (hpv) tat-tipi;felul ġenitali (kondiloma acuminata) każwalment relatat speċifiċi tipi ta' hpv. ara t-taqsimiet 4. 4 u 5. 1 għal informazzjoni importanti dwar id-dejta li tappoġġja din l-indikazzjoni. l-użu ta ' gardasil għandu jkun skond ir-rakkomandazzjonijiet uffiċjali.

Euroopa Liit - malta - EMA (European Medicines Agency)

merck sharp & dohme b.v. - vaċċin tal-papillomavirus uman [tipi 6, 11, 16, 18, 31, 33, 45, 52, 58] (rikombinanti, assorbjati) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - vaċċini għal papillomavirus - gardasil 9 huwa indikat għall-immunizzazzjoni attiva ta 'l-individwi mill-età ta'9 snin kontra l-hpv-mard:premalignant leżjonijiet u l-kanċer li jaffettwa l-ċerviċi, vulva, tal-vaġina u l-anus ikkawżat minn hpv ta' vaċċin typesgenital-felul (kondiloma acuminata) ikkawżata mill-speċifiċi tipi ta ' hpv. ara t-taqsimiet 4. 4 u 5. 1 għal tagħrif importanti dwar l-informazzjoni li ssostni dawn l-indikazzjonijiet. l-użu ta ' gardasil 9 għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Euroopa Liit - malta - EMA (European Medicines Agency)

corza medical gmbh - fibrinoġen uman, trombina umana - hemostasi, kirurġiċi - sustanzi kontra l-emorraġija - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

Euroopa Liit - malta - EMA (European Medicines Agency)

merck sharp dohme ltd - papillomavirus uman tip 6 l1 proteina, tal-papillomavirus uman tip 11 l1 proteina, tal-papillomavirus uman tip 16 l1 proteina, tal-papillomavirus uman tip 18 l1 proteina - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vaċċini - silgard huwa vaċċin għall-użu mill-età ta'9 snin għall-prevenzjoni ta': leżjonijiet ġenitali premalinni (ċervikali, tal-vulva u vaġinali), premalignant leżjonijiet anali, 'kanċers ċervikali u kanċer anali każwalment relatat ċerti onkoġeniċi-papillomavirus uman (hpv) tat-tipi;felul ġenitali (kondiloma acuminata) każwalment relatat speċifiċi tipi ta' hpv. ara t-taqsimiet 4. 4 u 5. 1 għal informazzjoni importanti dwar id-dejta li tappoġġja din l-indikazzjoni. l-użu ta ' silgard għandu jkun skond ir-rakkomandazzjonijiet uffiċjali.

Euroopa Liit - malta - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, tromboċitopenika, idjopatika - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Euroopa Liit - malta - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - sera immuni u immunoglobulini, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Euroopa Liit - malta - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosoppressanti - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Euroopa Liit - malta - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Euroopa Liit - malta - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosoppressanti - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Euroopa Liit - malta - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus eritematoso, sistemiku - immunosoppressanti - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.